{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:15:51Z","timestamp":1775582151799,"version":"3.50.1"},"reference-count":33,"publisher":"Microbiology Society","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"\n Introduction.<\/jats:bold>\n Procalcitonin has been recognized as a tool for effective antibiotic stewardship to reduce unnecessary antibiotic use; however, its effectiveness remains unknown in the oncology setting, where infections are common and antibiotics are frequently prescribed.\n <\/jats:p>\n \n Gap statement.<\/jats:bold>\n The utility of procalcitonin for effective antibiotic stewardship in people with solid organ cancers is unknown.\n <\/jats:p>\n \n Aim.<\/jats:bold>\n To evaluate the role of procalcitonin dynamics in solid organ cancer patients with suspected bacterial infections in predicting clinical outcomes and guiding antibiotic therapy decisions.\n <\/jats:p>\n \n Methodology.<\/jats:bold>\n A single-centre evaluation was conducted at the Bristol Haematology and Oncology Centre, studying consecutive admissions of adult patients with solid organ cancer over a 3-month period. In a population in which serum procalcitonin levels were sporadically measured to guide antibiotic therapy, they were measured as standard care on admission and at 48\u2009hours for patients admitted with a suspected bacterial infection. A threshold of 0.25\u2009ng\u2009ml\n \u22121<\/jats:sup>\n was used to distinguish between low and high procalcitonin levels. Cases that had persistently low procalcitonin levels were retrospectively analysed for the potential identification of patients who could have had their antibiotic treatment ceased 48\u2009hours into the antibiotic course.\n <\/jats:p>\n \n Results.<\/jats:bold>\n Seventy-seven\u2009cases with procalcitonin readings were recorded. Seventy (90.9%) cases received intravenous antibiotics during admission. Twenty-seven (35.1%) cases had persistently low procalcitonin, defined as <0.25\u2009ng\u2009ml\n \u22121<\/jats:sup>\n on consecutive measurements, interpreted as unlikely to have bacterial infection as suggested from previous literature. No objective microbiological evidence of bacterial infection was observed in these cases. Retrospective clinician reviews of the 27\u2009cases showed antibiotic therapy for 16 of the 27\u2009cases could have been stopped 48\u2009h into the admission, equivalent to a total reduction of up to 83\/778 (10.7%) antibiotic days.\n <\/jats:p>\n \n Conclusion.<\/jats:bold>\n Procalcitonin could provide a helpful adjunct for clinicians to consider antibiotic stewardship and help reduce unnecessary antibiotic use in the oncology setting.\n <\/jats:p>","DOI":"10.1099\/jmm.0.002145","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:16:41Z","timestamp":1775578601000},"source":"Crossref","is-referenced-by-count":0,"title":["Dynamic procalcitonin-guided antibiotic stewardship among cancer patients in the UK"],"prefix":"10.1099","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-3840","authenticated-orcid":false,"given":"Dowan","family":"Kwon","sequence":"first","affiliation":[{"name":"Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Williams","sequence":"additional","affiliation":[{"name":"Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Winter","sequence":"additional","affiliation":[{"name":"Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","article-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"O\u2019Neill","year":"2016","journal-title":"The review on antimicrobial resistance"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-017-0246-8"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30592-3"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00090-2"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.04.008"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.03.001"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-1181"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1297"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0347-y"},{"key":"R10","article-title":"Health Research Authority decision tool [Internet]","year":"2017"},{"key":"R11","article-title":"Tackling antimicrobial resistance 2019 to 2024: The UK\u2019s five-year national action plan","year":"2019"},{"key":"R12","first-page":"192","article-title":"A guide to bacterial culture identification and results interpretation","volume":"44","author":"Giuliano","year":"2019","journal-title":"P T"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-19"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7159.637"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmz066"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-019-1065-x"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.7835"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.3310\/hta19960"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1064934"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2112"},{"key":"R21","article-title":"Cancer statistics for England","author":"Baker","year":"2023","journal-title":"House of commons library"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg169"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.366"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00431-4"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.823705"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.002"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09156-x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011930"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164087"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2021-001339"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03658-4"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2132"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-838"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002145?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:16:43Z","timestamp":1775578603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.002145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.002145","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}